Crossover design and its application in late‐phase diabetes studies
Authors:
Open Access
- 18 August 2016
- journal article
- review article
- Published by Wiley in Journal of Diabetes
- Vol. 8 (5) , 610-618
Abstract
Crossover design has been widely used in late‐phase clinical studies, as well as in pharmacokinetic and pharmacodynamic, bioequivalence, and medical device studies; however, its interpretability and applicability continue to be debated. Herein we provide discussions around a crossover design's scientific benefit, applicability, and how it can be implemented in late‐phase diabetes studies by properly handling key issues: carryover effect, washout period, and baseline selection. Specifically, detailed considerations are provided about the validity and situations of having appropriate length of study duration to deal with carryover effects so that a washout period may not be needed. A simulation study and data mining results on 12 crossover late‐phase insulin clinical trials are presented to examine the discussion points and proposals.Keywords
This publication has 27 references indexed in Scilit:
- Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 DiabetesDiabetes Care, 2013
- Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthmaRespiratory Research, 2011
- Effects of exenatide twice daily versus sitagliptin on 24‐h glucose, glucoregulatory and hormonal measures: a randomized, double‐blind, crossover studyDiabetes, Obesity and Metabolism, 2011
- The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/BE) studies – an overviewComparative Effectiveness Research, 2011
- Cross‐over trials inStatistics in Medicine: the first ‘25’ yearsStatistics in Medicine, 2006
- Efficiency of the cross‐over design: an empirical estimationStatistics in Medicine, 2004
- Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer painBMJ, 2001
- THE NATURAL HISTORY OF TYPE 2 DIABETESPrimary Care: Clinics in Office Practice, 1999
- The performance of the two‐stage analysis of two‐treatment, two‐period crossover trialsStatistics in Medicine, 1989
- A Note on the Use of Nonparametric Methods in the Statistical Analysis of the Two-Period Changeover Design1982